During the 8th China International Import Expo (CIIE), Evinova China and Harbour BioMed announced a strategic collaboration to advance AI-driven drug development. The partnership brings together Evinova’s cutting-edge AI and digital health platforms with Harbour BioMed’s expertise in antibody therapeutics to accelerate the discovery and development of innovative biologics. Nate Zhang, General Manager of Evinova China, emphasized the significance of the alliance, stating, “Evinova leverages digital transformation insights from top global pharmaceutical companies to design AI-powered clinical development solutions and digital strategy consulting services. Our mission is to accelerate better health outcomes. To achieve this, we need to partner with innovative companies like Harbour BioMed—rooted in China but with global ambitions. Together, through our world-class AI technology platforms and deep therapeutic expertise, we can help take China-originated breakthrough assets from the laboratory to the world.” Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, added, “We are pleased to collaborate with Evinova to advance the application of AI in biotherapeutic development. Harbour BioMed has built a robust and differentiated product pipeline using our industry-leading Harbour Mice® technology platform. Through this collaboration, we look forward to applying AI to improve clinical study efficiency and accelerate the delivery of innovative therapies to patients worldwide.” Under the terms of the agreement, the two companies will jointly leverage AI and digital technologies to enhance the speed, accuracy, and efficiency of biologics development. The collaboration aims to create an open ecosystem for AI-powered research and development, fostering innovation across the life sciences sector. Evinova, a global health-tech business within the AstraZeneca Group, focuses on driving digital transformation in the life sciences industry. It combines science-based expertise, evidence-led rigor, and human-centered design to develop digital solutions that improve health outcomes. The company’s mission is to empower the life sciences community to deliver better, faster, and more accessible healthcare. Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company dedicated to discovering and developing novel antibody therapeutics in immunology and oncology. Its proprietary Harbour Mice® platform generates fully human monoclonal antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats. This foundation supports the company’s advanced technologies, including HBICE® (HCAb-based immune cell engagers) and HBICATM (HCAb-based bispecific immune cell antagonists), which enable the development of next-generation biologics with unique therapeutic potential. By integrating these platforms with a single B-cell cloning system, Harbour BioMed has created a highly efficient and distinctive antibody discovery engine. The collaboration marks a key step in China’s growing role in global biopharmaceutical innovation, combining local expertise with international digital capabilities to bring transformative therapies to patients faster.